11 research outputs found
Sickle Cell Disease and H3Africa: Enhancing Genomic Research on Cardiovascular Diseases in African Patients.
Sickle cell disease (SCD) has a high prevalence in sub-Saharan Africa. There are several cardiovascular phenotypes in SCD that contribute to its morbidity and mortality. SCD is characterised by marked clinical variability, with genetic factors playing key modulating roles. Studies in Tanzania and Cameroon have reported that singlenucleotide polymorphisms in BCL11A and HBS1L-MYB loci and co-inheritance of alpha-thalassaemia impact on foetal haemoglobin levels and clinical severity. The prevalence of overt stroke among SCD patients in Cameroon (6.7%) and Nigeria (8.7%) suggests a higher burden than in high-income countries. There is also some evidence of high burden of kidney disease and pulmonary hypertension in SCD; however, the burden and genetics of these cardiovascular conditions have seldom been investigated in Africa. Several H3Africa projects are focused on cardiovascular diseases and present major opportunities to build genome-based research on existing SCD platforms in Africa to transform the health outcomes of patients
Blinding Bilateral Hyperviscosity Retinopathy in a 43-Year-Old Nigerian Male with Lymphoplasmacytic Lymphoma: A Case Report and Management Challenges
Lymphoplasmacytic lymphomas are rare and may present with uncommon and devastating symptoms. We report a case of a 43-year-old male who presented with bleeding gums and sudden onset of bilateral blindness but was not on anticoagulants and had no family history of bleeding disorder. He had bilateral hyperpigmented infraorbital skin lesions, visual acuities (VA) of hand motion in both eyes (blindness), round and sluggish pupils, and bilateral diffuse and extensive retinal haemorrhages obliterating the retinal details with central visual field defects. The optical coherence tomography revealed retinal haemorrhage, oedema, detachment, and diffuse photoreceptors damage. Investigations revealed elevated ESR and β2 microglobulin, monoclonal peak on serum protein electrophoresis, high IG with lambda restriction on serum, and urine immunofixation with increased lymphocytes and plasma cells in the bone marrow. A diagnosis of lymphoplasmacytic lymphoma complicated by blinding hyperviscosity retinopathy was made. In the absence of an aphaeresis machine, he received four cycles of manual exchange blood transfusion (EBT) and commenced with chlorambucil/prednisolone due to difficulty in obtaining blood for continued EBT. His general condition and VA has improved and he is stable for more than six months into treatment
Sickle cell disease and H3Africa: enhancing genomic research on cardiovascular diseases in African patients
BackgroundSickle cell disease (SCD) has a high prevalence in sub-Saharan Africa. There are several cardiovascular phenotypes in SCD that contribute to its morbidity and mortality.DiscussionSCD is characterised by marked clinical variability, with genetic factors playing key modulating roles. Studies in Tanzania and Cameroon have reported that singlenucleotide polymorphisms in BCL11A and HBS1L-MYB loci and co-inheritance of alpha-thalassaemia impact on foetal haemoglobin levels and clinical severity. The prevalence of overt stroke among SCD patients in Cameroon (6.7%) and Nigeria (8.7%) suggests a higher burden than in high-income countries. There is also some evidence of high burden of kidney disease and pulmonary hypertension in SCD; however, the burden and genetics of these cardiovascular conditions have seldom been investigated in Africa.ConclusionsSeveral H3Africa projects are focused on cardiovascular diseases and present major opportunities to build genome-based research on existing SCD platforms in Africa to transform the health outcomes of patients
Recommended from our members
Establishing a Multi-Country Sickle Cell Disease Registry in Africa: Ethical Considerations
Sickle cell disease (SCD) is one of the most prevalent genetic conditions in sub-Saharan Africa. It is a chronic, lifelong disease often characterized by severe pain. However, SCD has received little investment terms of health research, though there is currently a growing pool of SCD data from health and research facilities in different countries. To facilitate research on SCD in Africa, the SickleInAfrica consortium has established a SickleInAfrica registry. The registry will store a systematic collection of longitudinal data from persons with SCD across sub-Saharan Africa, and currently, participants are being enrolled in Ghana, Nigeria, and Tanzania. In establishing this registry, the SickleInAfrica consortium decided to actively identify and anticipate possible ethical issues that may arise in the development and management of the registry. This was motivated, in part, by the near absence of well documented ethical issues for registry research in Africa, more-so for registries enrolling participants across multiple countries and for a genetic condition. The consortium aims to establish standards for the equitable use of data stored in the registry. This paper presents a comprehensive report on the ethical considerations that came up in setting up a genetic disease registry across multiple African countries and how they were addressed by the SickleInAfrica consortium. Major issues included: active involvement of patients in the initiation and management of the registry; questions of assent and re-consent; the importance of ensuring that fears of exploitation are not replicated in African-African research collaborations; and the importance of public engagement in the management of registries. Drawing on this experience, SickleInAfrica plans to set up an ethics helpdesk for genetic disease registries and research in Africa
Defining global strategies to improve outcomes in sickle cell disease ::a Lancet Haematology commission
All over the world, people with sickle cell disease (an inherited condition) have premature deaths and preventable severe chronic complications, which considerably affect their quality of life, career progression, and financial status. In addition, these people are often affected by stigmatisation or structural racism, which can contribute to stress and poor mental health. Inequalities affecting people with sickle cell disease are also reflected in the distribution of the disease—mainly in sub-Saharan Africa, India, and the Caribbean—whereas interventions, clinical trials, and funding are mostly available in North America, Europe, and the Middle East. Although some of these characteristics also affect people with other genetic diseases, the fate of people with sickle cell disease seems to be particularly unfair. Simple, effective interventions to reduce the mortality and morbidity associated with sickle cell disease are available. The main obstacle preventing better outcomes in this condition, which is a neglected disease, is associated with inequalities impacting the patient populations. The aim of this Commission is to highlight the problems associated with sickle cell disease and to identify achievable goals to improve outcomes both in the short and long term.
The ambition for the management of people with sickle cell disease is that curative treatments become available to every person with the condition. Although this would have seemed unrealistic a decade ago, developments in gene therapy make this potentially achievable, albeit in the distant future. Until these curative technologies are fully developed and become widely available, health-care professionals (with the support of policy makers, funders, etc) should make sure that a minimum standard of care (including screening, prophylaxis against infection, acute medical care, safe blood transfusion, and hydroxyurea) is available to all patients.
In considering what needs to be achieved to reduce the global burden of sickle cell disease and improve the quality of life of patients, this Commission focuses on five key areas: the epidemiology of sickle cell disease (Section 1); screening and prevention (Section 2); established and emerging treatments for the management of the disease (Section 3); cellular therapies with curative potential (Section 4); and training and education needs (Section 5). As clinicians, researchers, and patients, our objective to reduce the global burden of sickle cell disease aligns with wider public health aims to reduce inequalities, improve health for all, and develop personalised treatment options. We have observed in the past few years some long-awaited momentum following the development of innovative point-of-care testing devices, new approved drugs, and emerging curative options. Reducing the burden of sickle cell disease will require substantial financial and political commitment, but it will impact the lives of millions of patients and families worldwide and the lessons learned in achieving this goal would unarguably benefit society as a whole
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
All over the world, people with sickle cell disease (an
inherited condition) have premature deaths and prevenÂ
table severe chronic complications, which considerably
affect their quality of life, career progression, and finanÂ
cial status. In addition, these people are often affected by
stigmatisation or structural racism, which can contribute
to stress and poor mental health. Inequalities affecting
people with sickle cell disease are also reflected in the
distribution of the disease—mainly in subÂSaharan Africa,
India, and the Caribbean—whereas interventions,
clinical trials, and funding are mostly available in
North America, Europe, and the Middle East. Although
some of these characteristics also affect people with other
genetic diseases, the fate of people with sickle cell disease
seems to be particularly unfair. Simple, effective
interventions to reduce the mortality and morbidity
associated with sickle cell disease are available. The main
obstacle preventing better outcomes in this condition,
which is a neglected disease, is associated with
inequalities impacting the patient populations. The aim
of this Commission is to highlight the problems
associated with sickle cell disease and to identify
achievable goals to improve outcomes both in the short
and long term.
The ambition for the management of people with
sickle cell disease is that curative treatments become
available to every person with the condition. Although
this would have seemed unrealistic a decade ago,
developments in gene therapy make this potentially
achievable, albeit in the distant future. Until these
curative technologies are fully developed and become
widely available, healthÂcare professionals (with the
support of policy makers, funders, etc) should make sure
that a minimum standard of care (including screening,
prophylaxis against infection, acute medical care, safe
blood transfusion, and hydroxyurea) is available to all
patients.
In considering what needs to be achieved to reduce the
global burden of sickle cell disease and improve the
quality of life of patients, this Commission focuses on
five key areas: the epidemiology of sickle cell disease
(Section 1); screening and prevention (Section 2);
established and emerging treatments for the
management of the disease (Section 3); cellular therapies
with curative potential (Section 4); and training and
education needs (Section 5). As clinicians, researchers,
and patients, our objective to reduce the global burden of
sickle cell disease aligns with wider public health aims to
reduce inequalities, improve health for all, and develop
personalised treatment options. We have observed in the
past few years some longÂawaited momentum following
the development of innovative pointÂofÂcare testing
devices, new approved drugs, and emerging curative
options. Reducing the burden of sickle cell disease will
require substantial financial and political commitment,
but it will impact the lives of millions of patients and
families worldwide and the lessons learned in achieving
this goal would unarguably benefit society as a whol